Leave no one behind: optimizing kidney protection in type 1 diabetes

IF 46.7 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Nephrology Pub Date : 2026-08-13 DOI:10.1038/s41581-026-01116-7

Peter Rossing, Hiddo J. L. Heerspink

引用次数: 0

Abstract

Despite unprecedented advances in the treatment of non-diabetic chronic kidney disease (CKD) and CKD in type 2 diabetes mellitus in the past decade, no new drugs have been approved for CKD in type 1 diabetes mellitus. Urgent action is needed to develop new therapies and improve outcomes for this population.

查看原文本刊更多论文

不让任何人掉队：优化1型糖尿病的肾脏保护。

尽管在过去的十年中，非糖尿病性慢性肾脏疾病（CKD）和2型糖尿病慢性肾脏疾病的治疗取得了前所未有的进展，但尚未有新药被批准用于治疗1型糖尿病慢性肾脏疾病。需要采取紧急行动，为这一人群开发新的治疗方法并改善结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Nephrology 医学-泌尿学与肾脏学

CiteScore

39.00

自引率

1.20%

发文量

127

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Nephrology aims to be the premier source of reviews and commentaries for the scientific communities it serves. It strives to publish authoritative, accessible articles. Articles are enhanced with clearly understandable figures, tables, and other display items. Nature Reviews Nephrology publishes Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements. The content is relevant to nephrologists and basic science researchers. The broad scope of the journal ensures that the work reaches the widest possible audience.